Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it’s investigating the financials of Elon Musk’s pro-Trump PAC or producing our latest documentary, ‘The A Word’, which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Read more
Researchers began a highly anticipated study of two possible Ebola treatments on Thursday in hopes of fighting the still-growing outbreak in eastern Congo, as the World Health Organization announced the enrollment of the first participant.
The virus causing this outbreak, called Bundibugyo, is less common than others that cause Ebola disease and there are no specific treatments or vaccines for it. Already more than 1,400 people have been diagnosed and 438 have died, WHO Director-General Tedros Adhanom Ghebreyesus said Thursday.
Standard supportive care, especially if started early, can help and the WHO says more than 200 people have recovered. But there’s an urgent need for better options.
The trial “offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak,” Tedros said in a statement.
Researchers will be testing if two drugs could improve survival. One is Gilead Sciences’ remdesivir, a broad-acting antiviral approved to treat COVID-19 but that has shown some hints in lab tests that it may help fight the currently spreading virus. The other is Mapp Biopharmaceutical’s experimental MBP134, antibodies engineered to target Ebola viruses including Bundibugyo.
All patients enrolled in the trial would receive today’s best standard care and be randomly assigned to also receive remdesivir, MBP134, both or neither, said WHO research adviser Dr. Vasee Moorthy. Survival will be tracked for 28 days after starting treatment.
It could take months and possibly as many as 1,000 study participants to tell if either drug works, Moorthy cautioned, explaining that scientists could tell more quickly, and with fewer patients, if one or the other turns out to be highly effective.
Currently the study is being offered only in one Ebola treatment center in Congo’s Ituri province. The region has been hit hard by violence, including toward healthcare workers trying to fight a virus spread by contact with sick patients’ bodily fluids. Officials plan to expand to other locations once it is safe to do so.
Moorthy said enough of each drug had been donated by Gilead and the U.S. government, which has funded MBP134 research and owns those doses, for the trial. If either proves effective, the next step would be ensuring patients can continue to access the treatment outside the study.
The WHO-supported trial is a collaboration between Congo’s national biomedical research institute INRB, Britain’s Oxford University, Antwerp’s Institute of Tropical Medicine and other international health groups.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
